GI at [**Hospital1 **] performed ERCT [**2138-2-5**] with sphincterotomy with stent (8.5Fr 12 cm).
diverticulitis  Social History: widowed with children denied etoh/smoking/illicit drugs independent at senior living  Brief Hospital Course: On [**2138-2-7**], a cholangiogram was performed to evaluate the bile duct anatomy.
The patient's post ERCP plastic stent was noted within the common duct with extension superiorly into the superior common hepatic duct.
The right posterior ducts were not visualized likely due to high grade stricture or obstruction of central right posterior ducts.
On [**2-9**] she spiked a temperature to 102.5 with chills.
Blood and urine cultures were done.
On [**2-10**], bile was sent for culture growing Klebsiella pneumoniae.
Unasyn had been started prior to the Cholangiogram and this was continued for 5 days until bile cultures revealed that Klebsiella sensitivity to Unasyn was indeterminate.
On [**2-9**], a triple phase CT was done showing a large Klatskin-type hilar mass with imaging characteristics compatible with a cholangiocarcinoma.
A cardiac workup was started with TTE noting LVEF of 45-50%, mild to moderate MR, mild pulmonary systolic HTN.
O 2 2 liters and NTG 0.4 sl was given with relief.
EKG was unchanged, cardiac enzymes were negative.
It was noted that her hct was 26 and she was given 2 units of PRBC.
Hct increased to 33.
On [**2-13**], an ERCP was performed to remove the previously placed stent at OSH.
A chest CT was recommended to evaluate for any possible metastatic lesions for staging.
Discharge Disposition: Home With Service  Facility: [**Company 1519**]  Discharge Diagnosis: Unresectable cholangiocarcinoma   Discharge Condition: Stable   Discharge Instructions: Please call Dr [**Last Name (STitle) 4727**] office at [**Telephone/Fax (1) 673**] if you develop fever, chills, abdominal pain, increased yellowing of eyes or skin, [**Male First Name (un) 1658**] colored stools or other concerning symptoms.
You will be following up with Dr [**Last Name (STitle) **] as an outpatient for further evaluation of treatment options   Followup Instructions: [**First Name11 (Name Pattern1) **] [**Last Name (NamePattern1) 593**], MD Phone:[**Telephone/Fax (1) 22**] Date/Time:[**2138-3-5**] 9:30 [**First Name11 (Name Pattern1) **] [**Last Name (NamePattern4) 12766**], MD Phone:[**Telephone/Fax (1) 22**] Date/Time:[**2138-3-5**] 9:30 [**Hospital Ward Name 23**] Building [**Location (un) 24**]                                [**First Name11 (Name Pattern1) **] [**Last Name (NamePattern4) 707**] MD, [**MD Number(3) 709**]  Completed by:[**2138-2-20**
